Results from chemoradiotherapy for squamous cell cervical cancer with or without intracavitary brachytherapy

Delgado, Diogo; Figueiredo, André; Mendonça, V.; Jorge, Marília; Abdulrehman, M.; Pina, Maria Filomena de

doi:10.5114/jcb.2019.88116

Cited by 6 publications

(3 citation statements)

References 27 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCCC is characterized by an aggressive disease course and poor prognosis, with a 5-year survival rate of only 29% compared to 68% in other cervical cancer subtypes. 1,21,22 In this study, the 1-, 3-, and 5-year OS were 63.3%, 36.9%, and 30.2% respectively. Consistent with the findings of previous studies, 8 we confirmed that the FIGO stage is an important prognostic indicator.…”

Section: Discussionsupporting

confidence: 47%

<p>Prognostic Factors and Local Treatment Modalities of Small-Cell Carcinoma of the Cervix: An Analysis According to the International Federation of Gynecology and Obstetrics Stage</p>

Huang¹,

Gan²,

Cheng³

2020

CMAR

View full text Add to dashboard Cite

Purpose: Small-cell carcinoma of the cervix (SCCC) is a rare type of cervical cancer. This study aimed to investigate the clinicopathological characteristics and survival as well as the optimal local treatment modalities for SCCC. Patients and Methods: We retrospectively evaluated the data of patients diagnosed with SCCC between 1988 and 2015 in our institutionthose included in the Surveillance, Epidemiology, and End Results (SEER) database and those in the Periodical Database. Kaplan-Meier method and Cox regression proportional hazard methods were used to evaluate overall survival (OS). A nomogram that could predict OS was constructed based on the Cox proportional hazard model. Results: In total, 695 patients were included in this study. The 5-year overall survival in FIGO stage I-IIA and IIB-IV patients was 45.7% and 14.4%, respectively (P <0.01). Univariate and multivariate analyses showed that lymph node status (P <0.01) and cancerdirected surgery (P <0.01) were independent prognostic factors for FIGO I-IIA stage patients, and age (P <0.05), tumor size (P <0.01), chemotherapy (P <0.01) and radiation (P <0.01) were independent prognostic factors for FIGO stage IIB-IV patients. Conclusion: Better prognosis was associated with negative lymph node status, no lymphatic vasculature, surgery, and early-stage patients. Furthermore, our data showed that the prognosis and treatment pattern varied depending on the FIGO stage, and that optimal treatment modalities included radical surgery for early-stage SCCC and chemoradiotherapy for advanced-stage SCCC. It is helpful to assess the individual prognosis of SCCC patients and choose personalized treatment modalities.

show abstract

Section: Discussionsupporting

confidence: 47%

<p>Prognostic Factors and Local Treatment Modalities of Small-Cell Carcinoma of the Cervix: An Analysis According to the International Federation of Gynecology and Obstetrics Stage</p>

Huang¹,

Gan²,

Cheng³

2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Thus, an increased external pelvic dose will probably not compensate for exclusion of brachytherapy treatment. Prior studies have also confirmed the advantage of combined external and intracavitary therapy compared with external therapy alone [8,16,17]. The total dose (D90) to the HRCTV (external plus intracavitary) was significantly higher in the group treated with needles.…”

Section: Vaginal Toxicity (Only Recorded In the Igabt-group)mentioning

confidence: 80%

A comparison of external pelvic chemoradiation and high dose-rate conventional brachytherapy (BT) and image-guided adaptive brachytherapy (IGABT) in treatment of advanced cervical carcinomas

2020

ARCH Women Health Care

View full text Add to dashboard Cite

“…Over the past decade, very few studies evaluated the role of EBRT instead of BT boost. Due to old EBRT techniques delivering a suboptimal dose, and limited and different population studies, the results were almost disappointing (11)(12)(13).…”

Section: Cancer Diagnosis and Prognosismentioning

confidence: 99%

Stereotactic Body Radiation Therapy Boost in Patients With Cervical Cancer Ineligible for Brachytherapy

Facondo¹,

Vullo²,

Sanctis³

et al. 2021

CDP

View full text Add to dashboard Cite

Background: Standard treatment for locally advanced cervical cancer is external beam radiotherapy followed by brachytherapy (BT). Stereotactic body radiation therapy (SBRT) is a possible option for treating patients ineligible for BT. Patients and Methods: From October 2012 to July 2020, nine women with cervical cancer received SBRT to high-risk volumes. The Kaplan–Meier method was used to estimate the rates of overall and disease-free survival. Results: The median age was 52 years; 88% of patients had squamous carcinoma. Reasons for forgoing BT were cervical canal stenosis, treatment refusal and hematological disease. The median boost dose was 18 Gy and the median dose per fraction was 6 Gy. Median follow-up was 16 months. The median survival was 24 months, the actuarial 2-year OS rate was 70%, and median disease-free survival was 11 months. One grade 3 late vaginal toxicity was reported. No acute nor late grade 4 toxicities were observed. Conclusion: SBRT boost in patients with cervical cancer ineligible for BT led to acceptable survival outcomes and a safe toxicity profile.

show abstract

Results from chemoradiotherapy for squamous cell cervical cancer with or without intracavitary brachytherapy

Cited by 6 publications

References 27 publications

<p>Prognostic Factors and Local Treatment Modalities of Small-Cell Carcinoma of the Cervix: An Analysis According to the International Federation of Gynecology and Obstetrics Stage</p>

<p>Prognostic Factors and Local Treatment Modalities of Small-Cell Carcinoma of the Cervix: An Analysis According to the International Federation of Gynecology and Obstetrics Stage</p>

A comparison of external pelvic chemoradiation and high dose-rate conventional brachytherapy (BT) and image-guided adaptive brachytherapy (IGABT) in treatment of advanced cervical carcinomas

Stereotactic Body Radiation Therapy Boost in Patients With Cervical Cancer Ineligible for Brachytherapy

Contact Info

Product

Resources

About